Olesoxime (TRO19622) is an experimental drug formerly under development by the now-defunct French company Trophos as a treatment for a range of neuromuscular disorders. It has a cholesterol-like structure and belongs to the cholesterol-oxime family of mitochondrial pore modulators.[1][2]
^Martin LJ (August 2010). "Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis". IDrugs. 13 (8): 568–580. PMC 3058503. PMID 20721828.
^"Olesoxime". New Drugs Online Report. UK Medicines Information. Archived from the original on 2016-03-03.
Olesoxime (TRO19622) is an experimental drug formerly under development by the now-defunct French company Trophos as a treatment for a range of neuromuscular...
deal will centre on the Phase II and III spinal muscular atrophy drug olesoxime (TRO19622). In April 2015, Roche acquired CAPP Medical, and its chief...
entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622), a mitochondrial targeted compound developed to treat neurodegenerative...
enabling the survival of motor neurons even with low levels of SMN protein. Olesoxime was a proprietary neuroprotective compound developed by the French company...
mitochondria function (creatine, acetyl-L-carnitine, dexpramipexole, and olesoxime). Other drugs with a variety of mechanisms were tested in clinical trials...